Search - tctmd.com

Displaying 1 - 20 of 183

Sort: Relevancy | Date

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

April 10, 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

News Conference News ACC 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Michael O'Riordan

April 08, 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

April 03, 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

April 02, 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

March 31, 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

March 30, 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

April 12, 2024

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

News Conference News ACC 2024

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

April 11, 2024

Need a Statin for Primary Prevention? There’s an App for That

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

April 07, 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

April 07, 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.